

HeartFlow Plaque Analysis | DECODE Study


HeartFlow's AI-enabled Plaque Analysis provides physicians with actionable data to help more confidently assess patients' risk and provide optimal treatment.

STUDY OBJECTIVE

Assess the impact on clinical decision-making of the HeartFlow AI-Plaque Analysis across a range of patients with varying presentations and disease stages.

KEY RESULTS:

Physicians using the HeartFlow AI-Plaque Analysis **changed their management decisions for 66%** of patients compared to using CCTA alone.*



2 out of 3 patients

received a refined preventative management plan following physician review of the HeartFlow AI-Plaque Analysis.

Nearly **50%** of patients with a calcium score of 0 were reclassified.

STUDY DESIGN

Patient Selection: 100 patients varied by age, sex, race, and disease burden. Patients had varying levels of calcium (median CACS: 99.5) and CAD-RADS scores. Median age was 64 and 41% were female.

CCTA REPORT ONLY	CCTA REPORT + PLAQUE ANALYSIS
<ol style="list-style-type: none"> 1 Review demographics and medical history 2 Review CCTA report 3 Individually and then as a group determine management plan <ol style="list-style-type: none"> A. Medical therapy (Staging per table below) B. Order quantitative plaque analysis? C. Would you order FFR_{CT}? D. ICA with possible revascularization 	<ol style="list-style-type: none"> 1 Review demographics and medical history <ul style="list-style-type: none"> - Total plaque volume (TPV) - Calcified and non-calcified plaque volume - Disease burden and location 2 Individually and then as a group determine management plan <ol style="list-style-type: none"> A. Medical therapy (Staging per table below) B. Would you order FFR_{CT}? C. ICA with possible revascularization

Stage	Treatment [†]
0	GDMT
1	Low dose statin
2	High-intensity statin
3	High-intensity statin + PCSK-9 inhibitor + additional medications
3+	Escalation of therapy following review of Plaque report if stage 3 was chosen initially

STUDY CONCLUSIONS

- Physicians changed their management decisions for 66% of patients when using CCTA + HeartFlow AI-Plaque Analysis compared to CCTA alone.
- DECODE evaluated treatment reclassification across a broad range of calcium scores and stenosis severities with treatment changes remaining consistent across all.
- The HeartFlow AI-Plaque Analysis data was seen as additive information for medical management decision-making.

* DECODE Study, presented at SCCT 2023.

† Freeman, et al. AM J Med 2023.

Legal Disclaimer: The information provided by the HeartFlow FFR_{CT} Analysis and Plaque Analysis is intended to be used in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional judgment. The HeartFlow FFR_{CT} and Plaque Analysis may not be appropriate for all patients. See their respective indications for use for more information.

The HeartFlow FFR_{CT} Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States, Europe, Japan, and Canada. The Plaque Analysis has received FDA Clearance and is commercially available in the United States.